期刊文献+

C-erbB-2不同抗体在乳腺癌免疫组化染色中的表达情况比较

下载PDF
导出
摘要 目的研究C-erbB-2的3种不同抗体在乳腺癌免疫组化染色中的阳性表达情况,从中寻找最佳的克隆,减少在免疫组化染色中由于单抗的敏感性低而出现的假阴性导致的漏诊或误诊。方法一抗分别选用鼠及兔单抗C-erbB-2,invitrogen二步法免疫组化试剂盒染色,染色时用乙二胺四乙酸(EDTA)ph8.0的抗原修复液作高压锅高压抗原修复,37℃30~60min条件下孵育一抗。结果兔单抗(克隆号EP3)和鼠单抗(克隆号e2-4001+3B5)弱阳性和强阳性率均为34.7%,鼠单抗(克隆号B68)弱阳性和强阳性率只有16.6%;差异有统计学意义(<0.05)。虽然鼠单抗e2-4001+3B5阳性率与兔单抗EP3一样,且在平均阳性强度方面还稍占优势,因为(3+)比EP3多两例;然而其有3例在EP3与B68同为阴性的情况下经C-erbB-2染色细胞质中出现明显的非特异性着色,即单纯的胞浆染色,严重误导了结果的判断,根据标准,应定为假阳性。结论抗体克隆号的选择与结果分析关系密切,各种单克隆抗体不同克隆号有不同的阳性率,抗体选择应依据其特异性和敏感性指标,准确验证后使用。
作者 陶勇玲 宋云
机构地区 丽水市人民医院
出处 《现代实用医学》 2012年第1期61-63,共3页 Modern Practical Medicine
  • 相关文献

参考文献7

  • 1Wolff AC,Hammond ME,Schwarrtz JN.American society of clinical oncology/college of American pathologists guid-eline recommendation for human epider-mal growth factor testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145.
  • 2Molina R,Jo J,Filella X,et a1.C-erbB-2 oncoprotein in the sera and tissue of pati-ents with breast cancer.Utility in progno-sis[J].Anticancer Res,1996,16(4B):2295-300.
  • 3Gharib H,Papini E,Valcavi R,et a1.American Association of Clinical Endoc-rinologists and Associazione Medici En-docrinologi Medical Guidelines for clini-cal practice for the diagnosis and manage-ment of thyroid nodules[J].Endocr Pract,2006,12(1):163-102.
  • 4Rossi S,Laurino L,Furlanetto A,et al.Rabbit monoclonal antibodies:a com-parative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies[J].Am J Clin Pathol,2005,124(2):295-302.
  • 5van der Vegt B,de Bock GH,Bart J,et al.Validation of the4B5rabbit monoclonal antibody in determining Her-2/neu status in breast cancer[J].Modern Pathology,2009,22(7):879-886.
  • 6Cheuk W,Chan JK,Shek TW,et al.Iflammatory pseudotumor like follieula dendritic cell tumor:a distinctive low-gra-de malignant intra-abdominal neoplasm with consistent Epstein-Barr virus associ-ation[J].AM J Surgpathol,2001,25(6):721-731.
  • 7Francis GD,Dimeeh M,Giles L,et a1.Frequency and reliability of oestrogen re-ceptor,progesterone receptor and HER2 in breast carcinoma determined by immu-nohistochemistry in Australasia:results of the RCPA Quality Assurance Program[J].J Clin Pathol,2007,60(11):1277-1283.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部